GRP78 Activity Moderation as a Therapeutic Treatment against Obesity.
Dongjin PanYunzhu YangAihua NongZhenzhou TangQingxiao LiPublished in: International journal of environmental research and public health (2022)
Glucose-regulated protein 78 (GRP78), a molecular chaperone, is overexpressed in patients suffering from obesity, fatty liver, hyperlipidemia and diabetes. GRP78, therefore, can be not only a biomarker to predict the progression and prognosis of obesity and metabolic diseases but also a potential therapeutic target for anti-obesity treatment. In this paper, GRP78 inhibitors targeting its ATPase domain have been reviewed. Small molecules and proteins that directly bind GRP78 have been described. Putative mechanisms of GRP78 in regulating lipid metabolism were also summarized so as to investigate the role of GRP78 in obesity and other related diseases and provide a theoretical basis for the development and design of anti-obesity drugs targeting GRP78.
Keyphrases
- insulin resistance
- endoplasmic reticulum stress
- metabolic syndrome
- weight loss
- high fat diet induced
- type diabetes
- weight gain
- cell surface
- high fat diet
- cardiovascular disease
- adipose tissue
- end stage renal disease
- skeletal muscle
- cancer therapy
- newly diagnosed
- blood pressure
- small molecule
- chronic kidney disease
- body mass index
- climate change
- glycemic control
- blood glucose
- replacement therapy
- single molecule
- smoking cessation